T1	Participants 24 68	adults with established rheumatoid arthritis
T2	Participants 181 276	patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA)
T3	Participants 318 354	714 patients who received etanercept
T4	Participants 441 483	581 patients who enrolled in the extension
T5	Participants 1061 1119	356 patients who completed 6 years of etanercept treatment
T6	Participants 1274 1307	167 patients who completed Year 7
T7	Participants 1556 1583	patients with RA in general
